open access

Vol 89, No 5 (2021)
Review paper
Submitted: 2021-07-14
Accepted: 2021-08-25
Published online: 2021-10-28
Get Citation

Progressive fibrosis in interstitial lung diseases — proposed definition and management

Magdalena Maria Martusewicz-Boros1, Wojciech Jerzy Piotrowski2
DOI: 10.5603/ARM.a2021.0103
·
Pubmed: 34725808
·
Adv Respir Med 2021;89(5):505-510.
Affiliations
  1. 3rd Lung Diseases and Oncology Department, National Tuberculosis and Lung Diseases Reasearch Institute in Warsaw, Warsaw, Poland
  2. Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Poland

open access

Vol 89, No 5 (2021)
REVIEWS
Submitted: 2021-07-14
Accepted: 2021-08-25
Published online: 2021-10-28

Abstract

Interstitial lung diseases may have an unpredictably progressive course, which is manifested as progression of pulmonary fibrosis, causing an increasing impairment of lung function affecting a poor prognosis. The possibility of an effective antifibrotic treatment is a chance for patients to slow down the progression of the disease, perhaps even extend their life. For this reason, standardization of the definition as well as identification criteria for progressive fibrosis interstitial lung disease is a method for optimizing the management in this group of patients.

Abstract

Interstitial lung diseases may have an unpredictably progressive course, which is manifested as progression of pulmonary fibrosis, causing an increasing impairment of lung function affecting a poor prognosis. The possibility of an effective antifibrotic treatment is a chance for patients to slow down the progression of the disease, perhaps even extend their life. For this reason, standardization of the definition as well as identification criteria for progressive fibrosis interstitial lung disease is a method for optimizing the management in this group of patients.

Get Citation

Keywords

interstitial lung disease, progressive fibrosis, antifibrotic treatment

About this article
Title

Progressive fibrosis in interstitial lung diseases — proposed definition and management

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 5 (2021)

Article type

Review paper

Pages

505-510

Published online

2021-10-28

DOI

10.5603/ARM.a2021.0103

Pubmed

34725808

Bibliographic record

Adv Respir Med 2021;89(5):505-510.

Keywords

interstitial lung disease
progressive fibrosis
antifibrotic treatment

Authors

Magdalena Maria Martusewicz-Boros
Wojciech Jerzy Piotrowski

References (45)
  1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6): 733–748.
  2. George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020; 8(9): 925–934.
  3. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5): e44–e68.
  4. Piotrowski WJ, Bestry I, Białas AJ, et al. Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(1): 41–93.
  5. Kreuter M, Swigris J, Pittrow D, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019; 20(1): 59.
  6. Reichmann WM, Yu YF, Macaulay D, et al. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med. 2015; 15: 167.
  7. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3): 496–504.
  8. Richeldi L, Collard H, Jones M. Idiopathic pulmonary fibrosis. The Lancet. 2017; 389(10082): 1941–1952.
  9. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019; 381(18): 1718–1727.
  10. Highland KB, Distler O, Kuwana M, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol. 2017; 35 Suppl 106(4): 75–81.
  11. Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020; 8(2): 147–157.
  12. Torrisi SE, Kahn N, Wälscher J, et al. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulm Med. 2019; 19(1): 213.
  13. Wells AU, Brown KK, Flaherty KR, et al. What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018; 51(5).
  14. Nunes H, Schubel K, Piver D, et al. Nonspecific interstitial pneumonia: survival is influenced by the underlying cause. Eur Respir J. 2015; 45(3): 746–755.
  15. Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018; 73(4): 391–392.
  16. Lee JiY, Jin SM, Lee BJ, et al. Treatment response and long term follow-up results of nonspecific interstitial pneumonia. J Korean Med Sci. 2012; 27(6): 661–667.
  17. Goh NS, Hoyles RK, Denton CP, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. 2017; 69(8): 1670–1678.
  18. Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019; 35(11): 2015–2024.
  19. Olson A, Hartmann N, Patnaik P, et al. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. Adv Ther. 2021; 38(2): 854–867.
  20. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020; 55(6).
  21. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365(12): 1079–1087.
  22. Richeldi L, Bois Rdu, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Eng J Med. 2014; 370(22): 2071–2082.
  23. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779): 1760–1769.
  24. Nathan SD, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014; 189(7): 825–831.
  25. Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019; 6(1): e000397.
  26. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019; 7(1): 60–68.
  27. Cottin V, Koschel D, Günther A, et al. Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. ERJ Open Res. 2018; 4(4).
  28. Fisher M, Nathan SD, Hill C, et al. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. J Manag Care Spec Pharm. 2017; 23(3-b Suppl): S17–S24.
  29. Martusewicz-Boros M, Górska K. Nintedanib — efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis. Adv Respir Med. 2020; 88(6): 599–607.
  30. Raghu G, Wells AU, Nicholson AG, et al. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med. 2017; 195(1): 78–85.
  31. Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017; 72(4): 340–346.
  32. Brown KK, Flaherty KR, Cottin V, et al. Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019; 146: 42–48.
  33. Richeldi L, Kolb M, Jouneau S, et al. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018; 379(18): 1722–1731.
  34. Richeldi L, Kolb M, Jouneau S, et al. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020; 20(1): 3.
  35. Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res. 2018; 19(1): 141.
  36. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76(8): 1327–1339.
  37. Elhai M, Meune C, Boubaya M, et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012; 51(6): 1017–1026.
  38. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007; 176(10): 1026–1034.
  39. Khanna D, Yan X, Tashkin DP, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354(25): 2655–2666.
  40. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med. 2006; 354(25): 2707–2709.
  41. Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019; 38(10): 2673–2681.
  42. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020; 8(5): 453–460.
  43. Hughes G, Toellner H, Morris H, et al. Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016; 5(9).
  44. Antoniou K, Markopoulou K, Tzouvelekis A, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020; 6(1).
  45. Brunnemer E, Wälscher J, Tenenbaum S, et al. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2018; 95(5): 301–309.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl